Literature DB >> 18365420

A case of acute vascular rejection caused by endothelial-reactive non-HLA antibodies.

Jan Holgersson1, Elzafir Elsheikh, Per Grufman, Suchitra Sumitran-Holgersson, Gunnar Tydén.   

Abstract

We describe a female patient who, despite negative conventional cross-matches, lost her first kidney graft in an acute humoral rejection. Prior to the second, AB0-incompatible (A1B to A1) living-donor kidney transplant, the patient had negative T- and B-cell cross-matches but had a positive donor-reactive endothelial cell cross-match. Following pre-transplant protein A and GlycoSorb-ABO immunoadsorptions to remove blood group B and anti-endothelial cell antibodies, Mabthera, and IVIG administrations, she was successfully transplanted. By the second post-operative day, creatinine levels were down to 96 micromol/L from 611 micromol/L pre-operatively. On day 9 creatinine rose again, and on the same day the endothelial cell crossmatch became positive for IgG, whereas the T-cell cross-match remained negative and the anti-A1B titers remained low. A kidney biopsy taken on day 10 post-transplant showed a picture of an acute vascular, antibody-mediated rejection. Following rejection treatment and repeated protein A and Glyco-Sorb-ABO immunoadsorptions, the patient's kidney function was again normalized. The use of a recently developed kit (XM-ONE) for the detection of anti-endothelial cell antibodies allowed us to identify a patient at risk for developing acute antibody-mediated rejection as well as to monitor treatment efficacy and post-transplant complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18365420

Source DB:  PubMed          Journal:  Clin Transpl        ISSN: 0890-9016


  2 in total

1.  IgM antibodies towards pre-endothelial cells: strong indication for an association with accelerated rejection. A case report.

Authors:  Maria L Kafetzi; Aliki G Iniotaki; George C Liapis; Maria N Darema; Ilias I N Doxiadis; John N Boletis
Journal:  NDT Plus       Date:  2011-12

Review 2.  A Comprehensive Overview of the Clinical Relevance and Treatment Options for Antibody-mediated Rejection Associated With Non-HLA Antibodies.

Authors:  Tineke Kardol-Hoefnagel; Henny G Otten
Journal:  Transplantation       Date:  2021-07-01       Impact factor: 5.385

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.